Professor Richard Scolyer AO — pathologist, melanoma researcher, and co-medical director of Melanoma Institute Australia — died in 2026 at the age of 59, nearly three years after receiving a diagnosis of Grade 4 glioblastoma in June 2023. His death closes a career that placed him at the apex of melanoma pathology globally, and leaves unfinished a bold experimental attempt to apply immunotherapy principles — the very science he helped construct — to one of oncology's most intractable cancers.

A Career Built on Biospecimens and Benchmarks

Born in 1966, Scolyer spent the formative decades of his career embedded in the institutional infrastructure that would eventually make Australia a world reference point for melanoma research. He became the inaugural Melanoma and Skin Cancer Research Institute Pathology Fellow in 2001, and contributed to building the world's largest melanoma biospecimen bank, first established in 1998 — a resource whose depth underpins much of what is now known about melanoma's molecular heterogeneity.

His primary clinical base was Royal Prince Alfred Hospital in Sydney, where he held the position of Senior Staff Specialist in Tissue Pathology and Diagnostic Oncology. Concurrently, he served as a Conjoint Professor at Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, and as a Faculty Member at Melanoma Institute Australia alongside his long-time collaborator Professor Georgina Long.

The bibliometric record reinforces the scope of his contribution. As of February 2019, Scolyer was ranked the world's leading publisher in melanoma pathology and tenth globally across all melanoma research, according to Thomson Reuters ISI Web of Knowledge. That standing was later cited by the Melanoma Institute Australia as part of his institutional profile. Peer recognition followed in 2023 with both the Founders' Award from The American Society of Dermatopathology and the Distinguished Pathologist Award from the International Academy of Pathology Australasian Division.

The Immunotherapy Revolution He Helped Build

To understand what Scolyer's research meant in practice, it helps to hold a single fact in view: advanced melanoma was, less than a decade before 2024, a near-uniformly fatal diagnosis. The emergence of checkpoint inhibitor-based combination immunotherapy — an area in which Scolyer and Long's collaborative work at Melanoma Institute Australia played a central role — transformed the disease into one that is now considered curable in a meaningful proportion of patients. The arc from death sentence to manageable condition within roughly a decade is one of the faster reversals in modern oncology.

That revolution, forged through meticulous pathological classification and translational research, is what gave Scolyer and Long the credibility — and arguably the audacity — to attempt something entirely without precedent when his own diagnosis arrived.

Turning the Science on Himself

In June 2023, Scolyer was diagnosed with glioblastoma — Grade 4 primary brain cancer and, by any conventional metric, a disease with a median survival measured in months rather than years. Rather than proceed solely with standard-of-care treatment, Scolyer, working with Long, designed an experimental protocol that drew directly from the immunotherapy logic they had applied to melanoma.

He became the world's first brain cancer patient to receive pre-surgery combination immunotherapy as an experimental treatment, according to the Australian of the Year records. The regimen included a personalised cancer vaccine targeting the tumour's specific genetic markers, an approach calibrated to the molecular signature of his individual glioblastoma rather than to the disease class in aggregate. The logic — that neoadjuvant immunotherapy priming before surgical debulking could produce a more durable immune response — was borrowed from and adapted from their melanoma work.

The treatment did not produce a cure, but it bought time, and more consequentially, it generated a dataset. That data was sufficient to trigger an early-stage clinical trial in the United States, as reported by the BBC. The trial, now underway independently of Scolyer's own fate, is perhaps the clearest signal that his self-experimentation was not a private act of desperation but a structured scientific contribution — one with a prospective downstream.

We have seen this pattern before, in a different register, when Barry Marshall and Robin Warren's Helicobacter pylori work required Marshall to drink a bacterial solution to accelerate a paradigm shift the medical establishment was slow to accept. The mechanisms and diseases are entirely different, but the willingness to use one's own biology as primary evidence — to compress the gap between researcher and subject — carries a recognisable logic: sometimes the fastest path through institutional friction is the one the researcher walks personally.

Recognition and a Final Public Gesture

In January 2024, Prime Minister Anthony Albanese jointly named Scolyer and Long as 2024 Australians of the Year — an award framed around their combined contribution to revolutionising melanoma treatment and their pursuit of a breakthrough in glioblastoma, according to the Sydney Morning Herald. Scolyer had already received an Officer of the Order of Australia (AO) in June 2021 for distinguished service to medicine.

On 28 April 2026, the University of Sydney awarded Scolyer an honorary doctorate — a conferral made, it is worth noting, while he was still alive to receive it, per the University's own record. Weeks later, before his death, he published an open letter as a final goodbye, expressing thanks to Australians for their support throughout his illness. The letter, by accounts reported across multiple outlets, was characteristically direct — a gesture consistent with how he conducted his public communication about his diagnosis from the outset.

What Comes Next

Scolyer's death does not halt the science. The U.S. clinical trial his treatment protocol initiated remains active. Georgina Long, who co-designed the experimental regimen and continues as co-medical director of Melanoma Institute Australia, carries forward both the institutional program and the intellectual framework they developed jointly.

The broader question the trial is now tasked with answering is whether the immunological logic that reshaped melanoma outcomes can be adapted for glioblastoma — a cancer whose blood-brain barrier, immunosuppressive microenvironment, and high mutational heterogeneity present obstacles that checkpoint inhibition alone has not historically overcome. Scolyer's protocol, by introducing pre-surgical immunotherapy priming and individualised vaccine targeting, was an attempt to address at least two of those obstacles simultaneously.

Whether it works at scale, and in patients without Scolyer's specific tumour profile, is an open empirical question. The trial will answer it, or begin to. That, ultimately, is the nature of the contribution — not a concluded proof, but a rigorously constructed hypothesis, now being tested on the terms he established.

The Melanoma Institute Australia published a formal tribute marking his death. He was 59.